POPULATION PHARMACOKINETIC METHODS TO OPTIMIZE ANTIBIOTIC EFFECTS

被引:14
作者
AMSDEN, GW
BALLOW, CH
SCHENTAG, JJ
机构
[1] Center for Clinical Pharmacy Research, School of Pharmacy, State University of New York at Buffalo
[2] The Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, New York, 14209-1194
来源
DRUG INVESTIGATION | 1993年 / 5卷 / 05期
关键词
D O I
10.1007/BF03259590
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The concept of accelerating bacterial eradication and accomplishing a more rapid clinical cure by optimising dosing of antimicrobial agents is coming to fruition after many years of research. By integrating the pharmacokinetic parameters of an antibiotic with measures of microorganism susceptibility such as the minimum inhibitory concentration (MIC), it is possible to optimise both clinical and bacteriological cure. Recently, area under the inhibitory curve (AUIC) has been introduced as the 24-hour area under the curve (AUC) divided by the MIC. The AUIC has been shown to be an effective parameter to predict infectious outcome and it has the advantage that it can be easily calculated by estimating the patient's creatinine clearance and using population clearance of drugs vs creatinine clearance equations. In this review, total clearance vs creatinine clearance equations were derived for 53 antimicrobials, using pharmacokinetic data extracted from the literature. These equations were then validated by calculating half-life and AUC (for specific doses) and comparing the results to published values and ranges. In the validation phases the percentage error for each antibiotic equation was variable, ranging from 0.5 to 61% when estimating half-life, and 0.35 to 51% when estimating AUC. When a subset of antimicrobials was validated against values derived from studies of AUC vs decreasing creatinine clearance, the majority of percentage errors were within 0.35 to 56%, with only a minimal number of outliers over the studied ranges of renal function (0-129 ml/min/70kg). Possible explanations for these outliers include multiple routes of elimination and research based on populations different to those used to derive the original equation. Percentage errors were within acceptable ranges, when considering that most antimicrobials have a large therapeutic/toxic ratio. By targeting an AUIC value of 350, well above the theoretical threshold therapeutic value of 125, doses associated with an accelerated bacterial eradication rate are possible without substantially overdosing the patient. This remains true even if the calculated values from these equations are greater than a 50% overestimation.
引用
收藏
页码:256 / 268
页数:13
相关论文
共 54 条
  • [1] Aarons L., Vozeh S., Wenk M., Weiss P.H., Follath F., Population pharmacokinetics of tobramycin, British Journal of Clinical Pharmacology, 28, pp. 305-314, (1989)
  • [2] Adam D., De Visser I., Koeppe P., Pharmacokinetics of amoxicillin and clavulanic acid administered alone and in combination, Antimicrobial Agents and Chemotherapy, 22, pp. 353-357, (1982)
  • [3] Benet L.Z., Willia R.L., Design and optimization of dosage regimens
  • [4] pharmacokinetic data, Goodman and Gilman’s The Pharmacological Basis of Therapeutics, pp. 1655-1735, (1990)
  • [5] Blum R.A., Kohli R.K., Harrison N.J., Schentag J.J., Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with endstage renal disease on hemodialysis, Antimicrobial Agents and Chemotherapy, 33, pp. 1470-1476, (1989)
  • [6] Blum R.A., Schultz R.W., Schentag J.J., Pharmacokinetics of lome-floxacin in really compromised patients, Antimicrobial Agents and Chemotherapy, 34, pp. 2364-2368, (1990)
  • [7] Boeckh M., Lode H., Borner K., Hoffken G., Wagner J., Et al., Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers, Antimicrobial Agents and Chemotherapy, 32, pp. 92-95, (1988)
  • [8] Bolton W.K., Scheld W.M., Spyker D.A., Sande M.A., Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency, Antimicrobial Agents and Chemotherapy, 19, pp. 821-825, (1981)
  • [9] Colaizzi P.A., Polk R.E., Poynor W.J., Raffalovich A.C., Cefali E.A., Et al., Comparative pharmacokinetics of azlocillin and piperacillin in normal adults, Antimicrobial Agents and Chemotherapy, 29, pp. 938-940, (1986)
  • [10] Dettli L.C., Drug dosage in patients with renal disease, Clinical Pharmacology and Therapeutics, 16, pp. 274-280, (1974)